Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (131-140 of 323) with videos related to

Pageof 33
Sort By:
The Journal of Pathology|January 9, 2025
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcomeNicholas Trahearn, Chirine Sakr, Abhirup Banerjee, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Clinical Colorectal Cancer|May 30, 2020
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional AnalysisDaniele Rossini, Marco Maria Germani, Filippo Pagani, et al.
Oncotarget|January 28, 2017
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsMariantonietta Di Salvatore, Filippo Pietrantonio, Armando Orlandi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Future Oncology (London, England)|August 14, 2023
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 studyFederica Marmorino, Lorenzo Faggioni, Daniele Rossini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Clinical Colorectal Cancer|December 17, 2016
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, et al.
Pageof 33

Showing results (131-140 of 323) with videos related to

Sort By:
Pageof 33
The Journal of Pathology|January 9, 2025
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcomeNicholas Trahearn, Chirine Sakr, Abhirup Banerjee, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Clinical Colorectal Cancer|May 30, 2020
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional AnalysisDaniele Rossini, Marco Maria Germani, Filippo Pagani, et al.
Oncotarget|January 28, 2017
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsMariantonietta Di Salvatore, Filippo Pietrantonio, Armando Orlandi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Future Oncology (London, England)|August 14, 2023
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 studyFederica Marmorino, Lorenzo Faggioni, Daniele Rossini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Clinical Colorectal Cancer|December 17, 2016
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesFilippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, et al.
Pageof 33